People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2017 |
| Millendo Therapeutics, Inc. | — | Pharmaceuticals | Series C | $106.5M | $1.8B | 2017 |
| Calistoga Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $60.3M | $850.1M | 2009 |
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2015 |
| TRex Holdings Inc. | — | Biotechnology | Series C | $42.3M | $329.7M | 2024 |
| Cleave Biosciences, Inc. | — | Biotechnology | Series B | $37.9M | $475.1M | 2016 |
Carol Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carol Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 3 | 12 |
| Michael Ross | 1 | 18 |
| Kristina Burow | 1 | 16 |
| Andrew Schwab | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Peter Thompson | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Heath Lukatch | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| Tiba Aynechi | 1 | 9 |
| Joel Marcus | 1 | 9 |
| Alexandra Cantley | 1 | 8 |
| Richard Lin | 1 | 8 |
| Andrew J. Schwab | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Laura Shawver | 1 | 6 |
| James N. Topper | 1 | 5 |
| Robert Adelman | 1 | 5 |
| Robert Hoffman | 1 | 5 |
| Timothy Smith | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.